The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Analysts at StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

Ma Ya, a 25-year-old Chinese woman with degrees from Imperial College London and the University of Cambridge, left her high-paying job to become a zookeeper in Shanghai. Prioritising passion over ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...